Cardiovascular Diabetology

1. Cardiovasc Diabetol3 Feb 2026

   Echocardiography and inflammatory biomarkers for predicting mortality and major adverse cardiovascular events in type 1 diabetes

   Cohort studyT1D

2. Cardiovasc Diabetol2 Feb 2026

   Clinical subgroup-stratified plasma proteomic signatures improve risk prediction for myocardial infarction: SCORE2-Pro

   Diagnostic or prognostic study

3. Cardiovasc Diabetol30 Jan 2026

   A 5-hydroxymethylcytosine-based noninvasive model for acute myocardial infarction in type 2 diabetes: implications in cardiovascular outcomes from a 5-year median follow-up study

   Diagnostic or prognostic studyT2D & other

4. Cardiovasc Diabetol30 Jan 2026

   Comparative effects of second-line oral antidiabetic medications on atrial fibrillation risk in patients with type 2 diabetes: a nationwide retrospective cohort study

   Cohort studyT2D & other

5. Cardiovasc Diabetol29 Jan 2026

   Measures of comorbid cardiometabolic burden and cardiovascular disease risk in people with MRI-confirmed steatotic liver disease: a prospective cohort study

   Cohort studyLipids & liver

6. Cardiovasc Diabetol29 Jan 2026

   Risk score for lower-limb amputation and its ability to predict major kidney and cardiovascular events in people with type 1 diabetes

   Diagnostic or prognostic studyT1D

7. Cardiovasc Diabetol29 Jan 2026

   Associations of body mass index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study (a NorthStar substudy)

   Cohort studyObesity

8. Cardiovasc Diabetol28 Jan 2026

   Age-specific associations between blood pressure and cardiovascular disease, kidney disease, and death among individuals with type 2 diabetes: a population-based cohort study

   Cohort studyComplications

9. Cardiovasc Diabetol28 Jan 2026

   Development and validation of a neural network survival prediction model for ischemic heart disease

   Diagnostic or prognostic study

10. Cardiovasc Diabetol25 Jan 2026

    Association between the triglyceride-glucose-frailty index and all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: the mediating role of the poverty-income ratio

    Cohort studyLipids & liver

11. Cardiovasc Diabetol24 Jan 2026

    Impaired lymphangiogenesis in pericoronary adipose tissue correlates with diabetes-aggravated coronary atherosclerosis

    Mechanistic studyT2D & other

12. Cardiovasc Diabetol24 Jan 2026

    Progression to type 2 diabetes among post–myocardial infarction patients with overweight or obesity: a real-world cohort study

    Cohort studyT2D & other

13. Cardiovasc Diabetol24 Jan 2026

    Association between the combined c-reactive protein-triglyceride glucose index and hypertension with long-term stroke among cardiovascular-kidney-metabolic syndrome stages 0–3 population: a nationwide prospective cohort study

    Cohort studyLipids & liver

14. Cardiovasc Diabetol22 Jan 2026

    Joint association of estimated glucose disposal rate and aggregate index of systemic inflammation with mortality in general population: a nationwide prospective cohort study

    Cohort study

15. Cardiovasc Diabetol21 Jan 2026

    Prospective associations of triglyceride-glucose related indices with cardiovascular disease and mortality in individuals with metabolic syndrome: evidence from the UK biobank

    Cohort studyLipids & liver

16. Cardiovasc Diabetol20 Jan 2026

    Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes

    Randomized controlled trialT2D & other

17. Cardiovasc Diabetol20 Jan 2026

    Chronic kidney disease onset, progression, and cardiovascular outcomes: proteomics informs biology and risk stratification

    Cohort study

18. Cardiovasc Diabetol20 Jan 2026

    Triglyceride-glucose-related indices and cardiovascular outcomes in individuals with pre-frailty or frailty: insights from a prospective cohort analysis using UK Biobank data

    Cohort studyLipids & liver

19. Cardiovasc Diabetol20 Jan 2026

    Association between the triglyceride glucose index:Chinese visceral adiposity index (TyG-CVAI) and new-onset cardiovascular disease in middle-aged and older adults—insights from the China Health and Retirement Longitudinal Study (CHARLS)

    Cohort study

20. Cardiovasc Diabetol20 Jan 2026

    Integration of clinical and proteomic risk factors enhances prognostic modelling of incident vascular complications in type 2 diabetes

    Diagnostic or prognostic studyT2D & other

21. Cardiovasc Diabetol20 Jan 2026

    Association of cumulative cholesterol-HDL-glucose index with blood pressure changes and risk of new-onset hypertension in middle-aged and older adults: a cohort study

    Cohort studyLipids & liver

22. Cardiovasc Diabetol19 Jan 2026

    Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: evidence from international multi-cohort studies

    Cohort studyLipids & liver

23. Cardiovasc Diabetol18 Jan 2026

    Independent association of leg-height ratio with 15 cardiometabolic diseases

    Cohort studyT2D & other

24. Cardiovasc Diabetol18 Jan 2026

    Association between the newly proposed triglyceride glucose-a body shape index (TyG-ABSI) and atherosclerotic cardiovascular disease in the general population: modest diagnostic improvement compared with traditional TyG-related parameters

    Cross-sectional study

25. Cardiovasc Diabetol17 Jan 2026

    The predictive value of C-reactive protein-triglycerides-glucose index-waist-to-height ratio for stroke: a nationwide cohort study

    Cohort study

26. Cardiovasc Diabetol17 Jan 2026

    Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts

    Cohort studyLipids & liver

27. Cardiovasc Diabetol15 Jan 2026

    Epicardial adipose tissue mediates the association between circulating hsa-miR-4750-3p and coronary artery disease in patients with type 2 diabetes mellitus

    Cross-sectional studyT2D & other

28. Cardiovasc Diabetol12 Jan 2026

    Joint assessment of insulin resistance surrogate indices and basal metabolic rate for primary prevention of cardiometabolic multimorbidity: evidence from the China Health and Retirement Longitudinal Study (2011–2020)

    Cohort studyLipids & liver

29. Cardiovasc Diabetol12 Jan 2026

    Relationship between nine triglyceride-glucose-related indices and cardiometabolic multimorbidity incidence in patients with cardiovascular-kidney-metabolic syndrome stage 0–3: a nationwide prospective cohort study

    Cohort studyLipids & liver

30. Cardiovasc Diabetol8 Jan 2026

    Cardiac vagal activity is associated with insulin metabolism in heart failure: Results from the Myovasc study

    Cohort studyT2D & other

31. Cardiovasc Diabetol31 Dec 2025

    Association between combined atherogenic and frailty index and cardiovascular events: evidence from the CHARLS cohort

    Cohort study

32. Cardiovasc Diabetol31 Dec 2025

    Indications, prognosis, and complications of de Novo implantable cardioverter defibrillators in patients with and without type 2 diabetes: a nationwide registry-based cohort study

    Cohort studyT2D & other

33. Cardiovasc Diabetol30 Dec 2025

    Dapagliflozin modulates plasma lipidomic profile and urinary metabolite excretion in type 2 diabetes

    Randomized controlled trialT2D & other

34. Cardiovasc Diabetol29 Dec 2025

    SCORE2-diabetes for predicting coronary artery disease: a cardiac CT study in a diabetic moderate-risk region population

    Cohort studyT2D & other

35. Cardiovasc Diabetol29 Dec 2025

    Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction

    Mechanistic studyT2D & other

36. Cardiovasc Diabetol28 Dec 2025

    The effect of exercise characteristics on HbA1c and other cardiovascular risk factors in adults with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials

    Meta-analysisT2D & other

37. Cardiovasc Diabetol26 Dec 2025

    Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation

    Cross-sectional study

38. Cardiovasc Diabetol25 Dec 2025

    Distinct compositional alterations in plasma lipoproteins in type 2 diabetes: a cross-sectional study of healthy individuals and diabetics with and without cardiovascular comorbidities

    Cross-sectional studyT2D & other

39. Cardiovasc Diabetol24 Dec 2025

    Improved sex-specific cardiovascular risk prediction with multi-omics data in people with type 2 diabetes

    Diagnostic or prognostic studyT2D & other

40. Cardiovasc Diabetol24 Dec 2025

    Integrative oral and gut microbiome profiling highlights microbial correlates of complications in type 1 diabetes: a cross-sectional analysis

    Cross-sectional studyT1D

All 1,291 Briefs in ExploreShowing Briefs 201–240 of 1,291, newest first